An article in the Sept. 15, 1995, issue of BioWorld Todayon Alteon Inc. should have said the Ramsey, N.J.-basedcompany's two Phase III trials of pimagedine for Type Iand Type II diabetes are expected to enroll more than1,500 patients at 125 medical centers in the U.S. andCanada.

(c) 1997 American Health Consultants. All rights reserved.